DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

Authors
O'Connor, James P B
Jackson, Alan
Parker, Geoff J M
Jayson, Gordon C
Affiliation
Imaging Science and Biomedical Engineering, University of Manchester, Oxford Road, Manchester M13 9PT, UK.james.o'connor@manchester.ac.uk
Issue Date
2007-01-29

Metadata
Show full item record
Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
Citation
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. 2007, 96 (2):189-95 Br. J. Cancer
Journal
British Journal of Cancer
URI
http://hdl.handle.net/10541/71933
DOI
10.1038/sj.bjc.6603515
PubMed ID
17211479
Type
Article
Language
en
ISSN
0007-0920
Collections